BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21641889)

  • 1. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation.
    Mancuso A; Airoldi A; Vigano R; Pinzello G
    Dig Liver Dis; 2011 Sep; 43(9):754. PubMed ID: 21641889
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
    Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
    Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
    Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
    Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S; McTigue M; Finn RS; Busuttil RW
    Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
    Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
    Frenette CT; Frederick RT; Gish RG
    J Clin Gastroenterol; 2011 Sep; 45(8):733-7. PubMed ID: 20930642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coil extrusion from a gastric varice during sorafenib treatment for hepatocellular carcinoma.
    Lucas E; Aubourg A; Bacq Y; Perarnau JM
    Dig Liver Dis; 2011 Nov; 43(11):920. PubMed ID: 21763223
    [No Abstract]   [Full Text] [Related]  

  • 9. Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
    Diaz-Sanchez A; Rodriguez-Salas N; Aramendi T; Balbin E
    Dig Liver Dis; 2011 Apr; 43(4):333-4. PubMed ID: 21215716
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib-induced acute pancreatitis.
    Saadati H; Saif MW
    JOP; 2010 May; 11(3):283-4. PubMed ID: 20442531
    [No Abstract]   [Full Text] [Related]  

  • 11. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma.
    Liang CP; Yang CS; Shen JL; Chen YJ
    Br J Dermatol; 2011 Aug; 165(2):443-5. PubMed ID: 21495998
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hepatocellular carcinoma management in the era of sorafenib].
    Rosmorduc O
    Gastroenterol Clin Biol; 2009 Apr; 33(4):327-33. PubMed ID: 19321281
    [No Abstract]   [Full Text] [Related]  

  • 13. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
    Truesdale AE; Caldwell SH; Shah NL; Argo CK; Al-Osaimi AM; Schmitt TM; Northup PG
    Transpl Int; 2011 Oct; 24(10):991-8. PubMed ID: 21777298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
    Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
    Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyperkeratotic eczema of the nipple and areola associated with sorafenib treatment.
    Tougeron D; Wierzbicka-Hainaut E; Osdoit S; Chagneau-Derrode C; Yacoub M; Silvain C
    Eur J Dermatol; 2010; 20(6):854-6. PubMed ID: 20956109
    [No Abstract]   [Full Text] [Related]  

  • 16. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Staufer K; Fischer L; Seegers B; Vettorazzi E; Nashan B; Sterneck M
    Transpl Int; 2012 Nov; 25(11):1158-64. PubMed ID: 22882364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
    Saidi RF; Shah SA; Rawson AP; Grossman S; Piperdi B; Bozorgzadeh A
    Transplant Proc; 2010 Dec; 42(10):4582-4. PubMed ID: 21168742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
    Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P
    Digestion; 2011; 83(4):275-82. PubMed ID: 21282952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib-induced bilateral osteonecrosis of femoral heads.
    Guillet M; Walter T; Scoazec JY; Vial T; Lombard-Bohas C; Dumortier J
    J Clin Oncol; 2010 Jan; 28(2):e14. PubMed ID: 19884542
    [No Abstract]   [Full Text] [Related]  

  • 20. Sorafenib-induced hepatic encephalopathy.
    Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
    Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.